Psyllium

Metadata

• Common Names: Psyllium, Ispaghula, Indian Psyllium (English); Indischer Flohsamen (German)
• Botanical Name: Plantago ovata Forssk. (syn. Plantago ispaghula Roxb.)
• Plant Family: Plantaginaceae
• Part Used: Seed (Plantaginis ovatae semen); Seed husk/tegument (Plantaginis ovatae seminis tegumentum)
• Evidence Quality Rating: Strong (extensive clinical trial base; FDA-approved; well-established use per EMA)

Approved Indications

Commission E

• Habitual constipation
• Conditions where easy bowel movement with soft stools is desired (anal fissures, hemorrhoids, post-rectal/anal surgery, pregnancy)
• Supportive therapy for diarrhea of various causes
• Irritable bowel syndrome (irritable colon)
• Intestinal damage due to laxative abuse (rehabilitation)
• Diverticulitis (supportive)

ESCOP

• Habitual constipation (chronic constipation)
• Conditions requiring easy bowel movements with soft stools (anal fissures, hemorrhoids, post-surgical)
• Irritable bowel syndrome
• Diarrhea of various causes (supportive)
• Supportive treatment of dyslipidemia and hypertension (husk only)
• Gastritis and enteritis (supportive)

EMA/HMPC

• Well-established use (husk/tegument): Treatment of habitual constipation; conditions where easy defecation with soft stools is desirable
• Well-established use (husk): Irritable bowel syndrome (when constipation is the predominant symptom)
• Well-established use (husk): Adjunct to diet in the treatment of hypercholesterolemia
• Well-established use (seed): Treatment of habitual constipation
• This is one of the few herbal products where EMA grants full “well-established use” status for multiple indications

Agreement/Disagreement Between Bodies

• Strong consensus across all three bodies for constipation and related conditions
• All agree on IBS as an indication
• ESCOP and EMA also include cholesterol-lowering as an indication
• Commission E uniquely includes “intestinal damage due to laxative abuse” rehabilitation
• Commission E also uniquely includes diverticulitis
• The “well-established use” status from EMA reflects the strong evidence base

Conditions Treated

• Habitual / Chronic constipation
• Irritable bowel syndrome (IBS-C, IBS-M)
• Diarrhea (paradoxical but well-documented stool-normalizing effect)
• Anal fissures (stool softening)
• Hemorrhoids (stool softening)
• Post-surgical bowel management
• Mild to moderate hypercholesterolemia (adjunct)
• Diverticular disease (supportive)
• Intestinal rehabilitation after laxative abuse
• Type 2 diabetes (glycemic control, adjunct) [NEEDS-RESEARCH: emerging data]

Mechanism of Action

• Mucilage polysaccharides (arabinoxylan, primarily in the husk): Form a viscous gel on contact with water; swell to 10-20 times their volume
• Bulk-forming laxative: The gel increases fecal bulk and moisture content, stimulating peristalsis through mechanical distension of the intestinal wall
• Stool normalization: In constipation, the gel softens hard stool and increases bulk; in diarrhea, the gel absorbs excess water and firms loose stool — a bidirectional normalizing effect
• Prebiotic fermentation: Partially fermented by colonic bacteria, producing short-chain fatty acids (SCFAs — butyrate, propionate, acetate) that nourish colonocytes and support colonic health
• Cholesterol-lowering: Gel-forming fiber binds bile acids in the intestinal lumen, increasing fecal bile acid excretion and upregulating hepatic LDL receptor expression; 7-10% reduction in LDL cholesterol at therapeutic doses
• Glycemic modulation: Slows gastric emptying and glucose absorption, reducing postprandial glucose spikes
• IBS mechanism: Combination of stool normalization, reduced colonic transit time variability, and possible prebiotic effects on gut microbiome

Clinical Evidence Summary

Constipation — Gold Standard Among Fibers

• Designation as “gold standard”: Psyllium husk has been called “the gold standard in regulating bowel movements” among fiber types [Source: PMC 2024 review]
• Over 20 controlled clinical trials in constipated patients have demonstrated efficacy
• FDA-approved as an OTC drug for occasional constipation in the US
• Systematic reviews confirm consistent superiority over placebo for stool frequency, stool consistency, and ease of passage
• Comparison with lactulose: Some studies show comparable or superior efficacy

IBS

• Bijkerk et al. (2009): RCT (n=275); psyllium significantly improved IBS symptoms over 3 months vs placebo; bran did not
• NICE guidelines (UK): Recommend soluble fiber (psyllium) over insoluble fiber (bran) for IBS
• ACG guidelines (US, 2021): Conditional recommendation for soluble fiber (psyllium) in IBS

Cholesterol Lowering

• FDA health claim (1998): Approved health claim that soluble fiber from psyllium seed husk, when included in a diet low in saturated fat and cholesterol, may reduce the risk of coronary heart disease
• Multiple meta-analyses: Consistent 5-10% reduction in LDL cholesterol with 7-10 g/day psyllium
• AHA/ACC endorsement: Soluble fiber including psyllium recognized as a component of dietary management of dyslipidemia

Diarrhea

• Effective in both acute and chronic diarrhea, functioning as a stool normalizer rather than purely a laxative

European vs US/Anglophone Consensus

• Rare consensus: Psyllium is one of the few herbal products with broad agreement between European and US authorities
• FDA-approved OTC drug in the US (Metamucil, Konsyl, etc.)
• Well-established use per EMA in Europe
• Recommended in both ACG and NICE guidelines for IBS
• Available in pharmacies worldwide
• The main regional differences are in terminology (psyllium/ispaghula) and brand names rather than clinical acceptance
• US market is dominated by branded products (Metamucil); European market includes more pharmacy-grade preparations

Safety Profile

Contraindications

• Esophageal stricture or difficulty swallowing: Critical — risk of esophageal obstruction if product swells in the esophagus
• Bowel obstruction or fecal impaction
• Undiagnosed abdominal pain
• Known allergy to Plantago species (rare but documented)
• Conditions with abnormal narrowing of the GI tract

Drug Interactions

• Mechanical absorption interference: Psyllium gel can physically trap medications, reducing their absorption; separate administration by at least 2 hours before or after psyllium
• Levothyroxine: Separate by at least 4 hours (most clinicians advise extended separation)
• Lithium: May reduce absorption
• Carbamazepine: May reduce absorption
• Digoxin: May reduce absorption
• Insulin/oral antidiabetics: May enhance blood glucose lowering; monitor blood glucose
• No known severe pharmacological (as opposed to mechanical) drug interactions

Side Effects

• Bloating and flatulence (common, especially initially; usually resolves with continued use)
• Abdominal discomfort / cramping
• Choking and esophageal obstruction: FDA issued a final rule requiring warnings on granular psyllium products; always take with at least 240 mL (8 oz) of water
• Allergic reactions: Rhinitis, conjunctivitis, urticaria, asthma (primarily reported in healthcare workers with occupational exposure to psyllium powder)
• Anaphylaxis (very rare)

Pregnancy/Lactation

• Generally considered safe during pregnancy — bulk-forming fiber is not systemically absorbed
• Often recommended by European and US clinicians for pregnancy-related constipation
• Compatible with breastfeeding

Clinical Dosage

Forms and Ranges

• Psyllium husk (ispaghula husk): 3.5-7 g (1-2 rounded teaspoons) mixed in at least 240 mL water, 1-3 times daily
• Psyllium seed (whole): 10-30 g daily in divided doses with ample fluid
• Granular powder: Per manufacturer instructions, typically one serving (3.4 g) in 240 mL water, 1-3 times daily
• Capsules: Multiple capsules per dose to achieve equivalent fiber content
• For cholesterol: 7-10 g/day psyllium husk (divided doses with meals) for minimum 8 weeks
• Critical: Always take with at least 240 mL of water per dose; never swallow dry

Key Standardized Products

• Metamucil (Procter & Gamble): Most widely known US brand; various forms (powder, capsules, wafers)
• Konsyl (Konsyl Pharmaceuticals): USP-grade psyllium
• Fybogel (Reckitt Benckiser): Major UK/European brand (ispaghula husk)
• Indian Psyllium husk per European Pharmacopoeia: Minimum swelling index of 40
• Multiple generic pharmacy-grade products available in Europe

Sources

• EMA/HMPC Assessment Report on Plantago ovata Forssk., seminis tegumentum
• EMA/HMPC Herbal Monograph on Plantago ovata Forssk., semen; Plantago ovata Forssk., seminis tegumentum
• Commission E Monograph: Plantaginis ovatae semen; Plantaginis ovatae testa
• ESCOP Monographs: Plantaginis ovatae semen; Plantaginis ovatae testa (2020)
• Bijkerk CJ, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154
• FDA Health Claim: Soluble Fiber from Certain Foods and Risk of Coronary Heart Disease (21 CFR 101.81)
• Lacy BE, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44
• NICE CG61: Irritable bowel syndrome in adults
• McRorie JW, et al. Evidence-based approach to fiber supplements and clinically meaningful health benefits. Nutr Today. 2015;50(2):82-89
• FDA Final Rule: Laxative Drug Products for Over-the-Counter Human Use; Psyllium Ingredients in Granular Dosage Forms. Federal Register 72:59 (2007)

Connections

• Compare with Linseed/Flaxseed as fellow bulk-forming laxatives
• Compare with Senna for constipation — different mechanism (bulk-forming vs stimulant)
• Psyllium represents the “gold standard” end of the evidence spectrum in this herb collection
• The rare EU-US consensus on psyllium contrasts with the regulatory divergence seen for herbs like Wormwood and Milk Thistle